Berger-Sieczkowski, Evelyn
Endmayr, Verena
Haider, Carmen
Ricken, Gerda
Jauk, Philipp
Macher, Stefan
Pirker, Walter
Högl, Birgit
Heidbreder, Anna
Schnider, Peter
Bradley-Zechmeister, Eszter
Mariotto, Sara
Koneczny, Inga
Reinecke, Raphael
Kasprian, Gregor
Weber, Corinna
Bergmann, Melanie
Milenkovic, Ivan
Berger, Thomas
Gaig, Carles
Sabater, Lidia
Graus, Francesc
Gelpi, Ellen
Höftberger, Romana http://orcid.org/0000-0002-5769-1100
Funding for this research was provided by:
FWF (I4685-B, I6565-B)
Austrian Science Fund
Article History
Received: 31 May 2023
Revised: 11 August 2023
Accepted: 13 August 2023
First Online: 30 August 2023
Declarations
:
: E. Berger-Sieczkowski, V. Endmayr, C. Haider, G. Ricken, P. Jauk, S. Macher, Schnider, E. Bradley-Zechmeister, R. Reinecke, Reinecke Raphael, G. Kasprian, C. Weber, M. Bergmann, C. Gaig, L. Sabater, and E. Gelpi report no relevant disclosures. I. Koneczny has participated in meetings sponsored by Alexion. I. Milenkovic has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from: UCB, Sanofi-Genzyme, BioMarin and Takeda. A. Heidbreder reports speaker honoraria for UCB, Bioprojet, Idorsia, Medice, Jazz Pharmaceuticals. B. Högl reports speaker honoraria Jazz and Abbvie and advisor feed from Lundbeck. S. Mariotto reports speaker honoraria from Biogen, Sanofy, and Novartis. T. Berger has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for MS: Allergan, Biogen, Biologix, Bionorica, BMS/Celgene, Eisei, Janssen-Cilag, MedDay, Merck, Novartis, Roche, Sandoz, Sanofi-Genzyme, Teva, UCB. His institution has received financial support in the past 12 months by unrestricted research grants (Bayer, Biogen, BMS/Celgene, Merck, Novartis, Roche, Sanofi-Genzyme, Teva) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, BMS/Celgene, Merck, Novartis, Roche, Sanofi-Aventis, Teva. R. Höftberger reports speaker honoraria from Novartis and Biogen. The Medical University of Vienna (Austria; employer of Dr. Höftberger) receives payment for antibody assays and for antibody validation experiments organized by Euroimmun (Lübeck, Germany). Dr. F. Graus holds a patent licensed to Euroimmun for the use of IgLON5 in an autoantibody test, for which he receives royalties, and receives honoraria from MedLink Neurology for his role as associate editor. W. Pirker attended advisory boards by Stada, AbbVie Pharma, Merz and Bial. He received travel grants and educational support from Boehringer Ingelheim, AOP Pharma as well as lecturing honoraria from GE, UCB, Bial, Stada, AOP Orphan, AbbVie, Medtronic and Merz Pharma.